Radiopharmaceuticals requirement is necessary to support the department of radiology, nuclear medicine clinic.
Ended Purchase Order Awarded Last action
- Contract number
- W81K0025PA260
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $187,899
Award facts
- Contract value 100% obligated
- $187,899.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- JBSA FT SAM HOUSTON, TX 78234, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $187,899 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a $187,899.40 firm fixed-price purchase order to Sofie CO. (doing business as IBA Molecular) on October 1, 2025, with completion targeted for September 30, 2026. This contract provides radiopharmaceuticals to support the Department of Radiology and Nuclear Medicine Clinic at Joint Base San Antonio Fort Sam Houston in Texas. No set-aside designation was applied to this award. Sofie CO., a for-profit subsidiary of Sofie Biosciences headquartered in Sterling, Virginia, specializes in the development, production, and delivery of molecular diagnostics and therapeutic radiopharmaceuticals, with particular expertise in positron emission tomography (PET) imaging agents used for cancer detection and neurological imaging.
This purchase order represents a task order or direct procurement under Sofie CO.'s broader relationship with the Defense Health Agency, which maintains a $6.5 million master blanket purchase agreement for pharmaceutical supplies from which numerous task orders have been issued. The contractor's federal healthcare portfolio includes an extensive array of radiopharmaceuticals such as PYLARIFY (piflufolastat F-18) for prostate cancer detection, NEURACEQ (florbetaben F-18) for Alzheimer's disease imaging, F-18 fluorodeoxyglucose for general oncology imaging, and various gallium and copper-based radiopharmaceuticals for specialized diagnostic applications. Sofie CO. maintains full compliance with U.S. Nuclear Regulatory Commission and Food and Drug Administration licensing requirements and has established a proven track record supplying critical radiopharmaceuticals to military treatment facilities and veteran healthcare systems across the nation.
Quick answers
Who was awarded contract W81K0025PA260?
W81K0025PA260 was awarded to Sofie CO. by Medical Command (Department of the Army) on October 1, 2025.
How much is contract W81K0025PA260 worth?
The government has obligated $187,899 on W81K0025PA260.
Which agency awarded contract W81K0025PA260?
Medical Command (Department of the Army) awarded W81K0025PA260, with funding from Defense Health Agency (Department of Defense).
Was contract W81K0025PA260 competed?
The extent of competition for W81K0025PA260 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award